Sara M. Tinsley, PhD, APRN, AOCN - Therapeutic Advancements in Myelodysplastic Syndromes: Bridging the Gap Between Patient Safety and Quality Care Through the Latest Science and Evidence-Based Learnin

Go online to PeerView.com/EQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS annual meeting, our expert panel discusses tactics on how to maximize clinical outcomes for their lower- and higher-risk patients with myelodysplastic syndromes (MDS), with a focus on current and emerging treatment options. Hear practical insights and real-world case discussions and get informed on key safety and efficacy evidence for the treatment of MDS, and hear how an interprofessional-team approach can improve patient care. Upon completion of this accredited CE activity, participants should be better able to: Review clinical presentation, diagnostic-prognostic workups, risk stratification, and identification of transfusion needs of patients with MDS, Interpret recent clinical evidence on currently approved and innovative emerging treatment strategies for managing low-risk as well as high-risk patients with MDS, Develop educational strategies for patients with MDS related to therapeutic expectations, adherence, safety considerations, and differences among novel agent classes, Employ strategies to manage treatment-related adverse events to enhance quality of life for patients with MDS.